Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1<i>H</i>-Indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin
作者:Qinghui Wang、Kinsie E. Arnst、Yuxi Wang、Gyanendra Kumar、Dejian Ma、Stephen W. White、Duane D. Miller、Weimin Li、Wei Li
DOI:10.1021/acs.jmedchem.9b00706
日期:2019.7.25
10ab and 10bb in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft
ABI-231是一种有效的,口服生物利用的微管蛋白抑制剂,可与秋水仙碱结合位点相互作用,目前正在接受前列腺癌的临床试验。在与微管蛋白复合的ABI-231晶体结构的指导下,我们围绕3-吲哚部分进行了结构-活性关系研究,从而发现了几种有效的ABI-231类似物,最著名的是10ab和10bb。与微管蛋白复合的10ab和10bb的晶体结构证实了它们与秋水仙碱位点的分子相互作用得到了改善。在体外,生物学研究表明,新的ABI-231类似物可破坏微管蛋白聚合,促进微管碎裂并抑制癌细胞迁移。体内,类似物10bb不仅在黑素瘤异种移植模型中显着抑制原发性肿瘤生长并减少肿瘤转移,而且在抗紫杉烷的PC-3 / TxR模型中显示出显着的克服紫杉醇抗性的能力。此外,药理学筛选表明10bb潜在脱靶功能的风险较低。